Lately, we’ve seen social media initiatives by AstraZeneca and other pharmaceutical companies roundly criticized by bloggers like me and “disgruntled patients.” Many of my Twitter friends and other colleagues often cringe when they see us critics cutting up the goose that they believe is laying social media “golden eggs;” i.e, projects that improve their bottom lines.
The fear is that if these first steps by pharma are too harshly scrutinized and criticized, the drug industry will shy away from getting more involved in social media.
Read this entire OpEd piece by John Mack here:
http://www.news.pharma-mkting.com/PMNews_104_Upfront.pdf
